Using surrogate information to improve confirmatory platform trial with sample size re-estimation

References

• Angus, D. C., B. M. Alexander, S. Berry, M. Buxton, R. Lewis, M. Paoloni, S. A. R. Webb, S. Arnold, A. Barker, D. A. Berry, et al. 2019. Adaptive platform trials: Definition, design, conduct and reporting considerations. Nature Reviews. Drug Discovery 18 (10):797–807. doi:10.1038/s41573-019-0034-3.
   PubMed Web of Science ®Google Scholar
• Bai, X., Q. Deng, and D. Liu. 2020. Multiplicity issues for platform trials with a shared control arm. Journal of Biopharmaceutical Statistics 30 (6):1077–1090. doi:10.1080/10543406.2020.1821703.
   PubMed Web of Science ®Google Scholar
• Benboubker, L., M. A. Dimopoulos, A. Dispenzieri, J. Catalano, A. R. Belch, M. Cavo, A. Pinto, K. Weisel, H. Ludwig, N. Bahlis, et al. 2014. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. New England Journal of Medicine 371 (10):906–917. doi:10.1056/nejmoa1402551.
   PubMed Web of Science ®Google Scholar
• Berry, D. A., S. Zhou, H. Higley, L. Mukundan, S. Fu, G. H. Reaman, and J. P. Radich. 2017. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: A meta-analysis. JAMA Oncology 3 (7):e170580–e170580. doi:10.1001/jamaoncol.2017.0580.
   PubMed Web of Science ®Google Scholar
• Blumenthal, G. M., S. W. Karuri, H. Zhang, L. Zhang, S. Khozin, D. Kazandjian, S. Tang, R. Sridhara, P. Keegan, and R. Pazdur. 2015. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US food and drug administration trial-level and patient-level analyses. Journal of Clinical Oncology 33 (9):1008–1014. doi:10.1200/JCO.2014.59.0489.
   PubMed Web of Science ®Google Scholar
• Borghaei, H., L. Paz-Ares, L. Horn, D. R. Spigel, M. Steins, N. E. Ready, L. Q. Chow, E. E. Vokes, E. Felip, E. Holgado, et al. 2015. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New England Journal of Medicine 373 (17):1627–1639. doi:10.1056/nejmoa1507643.
   PubMed Web of Science ®Google Scholar
• Chang, W. H., and C. Chuang-Stein. 2004. Type I error and power in trials with one interim futility analysis. Pharmaceutical Statistics 3 (1):51–59. doi:10.1002/pst.93.
   Web of Science ®Google Scholar
• Chen, Y. H. J., D. L. DeMets, and K. K. G. Lan. 2004. Increasing the sample size when the unblinded interim result is promising. Statistics in Medicine 23 (7):1023–1038. doi:10.1002/sim.1688.
   PubMed Web of Science ®Google Scholar
• Cui, L., H. M. J. Hung, and S. J. Wang. 1999. Modification of sample size in group sequential clinical trials. Biometrics 55 (3):853–857. doi:10.1111/j.0006-341X.1999.00853.x.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. 2014. Guidance for industry: Expedited programs for serious conditions. Washington DC, USA: Food and Drug Administration.
   Google Scholar
• Food and Drug Administration. 2018a. Master protocols: Efficient clinical trial design strategies to expedite development of oncology drugs and biologics. Washington DC, USA: Food and Drug Administration.
   Google Scholar
• Food and Drug Administration. 2018b. Clinical trial endpoints for the approval of cancer drugs and biologics. Washington DC, USA: Food and Drug Administration.
   Google Scholar
• Friede, T., N. Stallard, and N. Parsons. 2020. Adaptive seamless clinical trials using early outcomes for treatment or subgroup selection: Methods, simulation model and their implementation in R. Biometrical Journal 62 (5):1264–1283. doi:10.1002/bimj.201900020.
   PubMed Web of Science ®Google Scholar
• Harousseau, J. L., A. Palumbo, P. G. Richardson, R. Schlag, M. A. Dimopoulos, O. Shpilberg, and M. Komarnicki. 2010. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 Vista study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. blood. The Journal of the American Society of Hematology 116 (19):3743–3750.
   Google Scholar
• Heerspink, H. J. L., and V. Perkovic. 2018. Trial design innovations to accelerate therapeutic advances in chronic kidney disease: Moving from single trials to an ongoing platform. Clinical Journal of the American Society of Nephrology 13 (6):946–948. doi:10.2215/CJN.01290118.
   PubMed Web of Science ®Google Scholar
• I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients (I-SPY_COVID) 2020. Accessed 21 July, 2021. https://clinicaltrials.gov/ct2/show/NCT04488081
   Google Scholar
• Jenkins, M., A. Stone, and C. Jennison. 2011. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10 (4):347–356. doi:10.1002/pst.472.
   PubMed Web of Science ®Google Scholar
• Jennison, C., and B. W. Turnbull. 1999. Group sequential methods with applications to clinical trials. Boca Raton, Florida, U.S.A: CRC Press.
   Google Scholar
• Lehmacher, W., and G. Wassmer. 1999. Adaptive sample size calculations in group sequential trials. Biometrics 55 (4):1286–1290. doi:10.1111/j.0006-341X.1999.01286.x.
   PubMed Web of Science ®Google Scholar
• Li, Q., J. Lin, and Y. Lin. 2020. Adaptive design implementation in confirmatory trials: Methods, practical considerations and case studies. Contemporary Clinical Trials 98 (July):106096. doi:10.1016/j.cct.2020.106096.
   PubMedGoogle Scholar
• Li, Q., J. Lin, M. Liu, L. Wu, and Y. Liu. 2021. Utilizing surrogate endpoints in adaptive designs with delayed treatment effect. Statistics in Biopharmaceutical Research. doi:10.1080/19466315.2021.1938203.
   PubMed Web of Science ®Google Scholar
• Lin, J., and V. Bunn. 2017. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials. Contemporary Clinical Trials 54:48–59. doi:10.1016/j.cct.2017.01.003.
   PubMed Web of Science ®Google Scholar
• Lin, J., L. Lin, V. Bunn, and R. Liu. 2019. Adaptive randomization for master protocols in precision medicine. In Contemporary biostatistics with biopharmaceutical application, 251–270. Springer International Publishing.
   Google Scholar
• Liu, M., Q. Li, J. Lin, Y. Lin, and E. Hoffman. 2021. Innovative trial designs and analyses for vaccine clinical development. Contemporary Clinical Trials 100:106225. doi:10.1016/j.cct.2020.106225.
   PubMed Web of Science ®Google Scholar
• Lloyd, I. (2020). Pharma RD Annual Review 2020 Whitepaper. Pharma Intelligence. Accessed 15 April, 2020. https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2020/files/whitepapers/rd-review-2020-whitepaper.pdf
   Google Scholar
• Marcus, R., E. Peritz, and K. R. Gabriel. 1976. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. doi:10.1093/biomet/63.3.655.
   Web of Science ®Google Scholar
• Mehta, C. R., and S. J. Pocock. 2011. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Statistics in Medicine 30 (28):3267–3284. doi:10.1002/sim.4102.
   PubMed Web of Science ®Google Scholar
• Meyer, E. L., P. Mesenbrink, C. Dunger-Baldauf, H. J. Fülle, E. Glimm, Y. Li, M. Posch, and F. König. 2020. The evolution of master protocol clinical trial designs: a systematic literature review. Clinical Therapeutics 42 (7):1330–1360. doi:10.1016/j.clinthera.2020.05.010.
   PubMed Web of Science ®Google Scholar
• Munshi, N. C., H. Avet-Loiseau, A. C. Rawstron, R. G. Owen, J. A. Child, A. Thakurta, and W. M. Gregory. 2017. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis. JAMA Oncology 3 (1):28–35. doi:10.1001/jamaoncol.2016.3160.
   PubMed Web of Science ®Google Scholar
• Pallmann, P., A. W. Bedding, B. Choodari-Oskooei, M. Dimairo, L. Flight, L. V. Hampson, J. Holmes, A. P. Mander, L. Odondi, M. R. Sydes, et al. 2018. Adaptive designs in clinical trials: Why use them, and how to run and report them. BMC Medicine 16 (1):1–15. doi:10.1186/s12916-018-1017-7.
   Google Scholar
• Park, J. J. H., O. Harari, L. Dron, R. T. Lester, K. Thorlund, and E. J. Mills. 2020. An overview of platform trials with a checklist for clinical readers. Journal of Clinical Epidemiology 125:1–8. doi:10.1016/j.jclinepi.2020.04.025.
   PubMed Web of Science ®Google Scholar
• Proschan, M. A., K. G. Lan, and J. T. Wittes. 2006. Statistical monitoring of clinical trials: A unified approach. New York, NY, U.S.A: Springer Science & Business Media.
   Google Scholar
• Reck, M., D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, et al. 2016. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. New England Journal of Medicine 375 (19):1823–1833. doi:10.1056/nejmoa1606774.
   PubMed Web of Science ®Google Scholar
• RECOVERY (Randomized Evaluation of COVID-19 Therapy). 2020. Accessed 7 April, 2022. https://clinicaltrials.gov/ct2/show/NCT04381936
   Google Scholar
• Renfro, L. A., H. Mallick, M. W. An, D. J. Sargent, and S. J. Mandrekar. 2016. Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews 43:74–82. doi:10.1016/j.ctrv.2015.12.008.
   PubMed Web of Science ®Google Scholar
• Simes, R. J. 1986. An Improved Bonferroni Procedure for Multiple Tests of Significance. Biometrika 73 (3):751–754. doi:10.1093/biomet/73.3.751.
   Web of Science ®Google Scholar
• Webster, R. M. 2016. Combination therapies in oncology. Nature Reviews. Drug Discovery 15 (2):81. doi:10.1038/nrd.2016.3.
   PubMed Web of Science ®Google Scholar
• Wu, L., Q. Li, M. Liu, and J. Lin. 2022. Incorporating surrogate information for adaptive subgroup enrichment design with sample size re-estimation. Statistics in Biopharmaceutical Research. doi:10.1080/19466315.2022.2046150.
   Web of Science ®Google Scholar
• Yang, S., and R. Prentice. 2005. Semiparametric analysis of short-term and long-term hazard ratios with two-sample survival data. Biometrika 92 (1):1–17. doi:10.1093/biomet/92.1.1.
   Web of Science ®Google Scholar